B. Douglas Smith, MD Professor of Oncology Division of Hematologic Malignancies Sidney Kimmel Cancer Center at Johns Hopkins Baltimore, MD
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the bone marrow, accounting for 15% of adult leukemias. Targeted therapy with tyrosine kinase inhibitors (TKIs) has dramatically improved 10-year overall survival for patients with CML from 20% to 80%-90%. To determine the best treatment approach for patients with CML, clinicians must thoroughly understand how to monitor treatment response. The correct interpretation of milestone assessments holds the key to improving physicians’ ability to maintain patients on treatment, to optimize sequencing of treatments if needed, and to improve the quality of patient outcomes.
Presented by the Johns Hopkins University School of Medicine in collaboration with MCM Education.
This educational activity is designed to meet the needs of hematologists and oncologists directly involved in the care of patients with chronic myeloid leukemia. There are no prerequisites.
Upon completion of this educational activity, the participant should be able to:
Create an evidence-based treatment plan for a newly diagnosed CML patient, including a long-term response monitoring program that aligns with current clinical practice guidelines.
Correctly perform and interpret milestone assessments, leading to evidence-based decisions regarding dose escalation, switching to alternative therapies, and toxicity management.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
B. Douglas Smith, MD, has no conflicts of interest to disclose.
Amir Fathi, MD, has disclosed that he has served as a consultant or advisor for Agios Pharmaceuticals, Ariad Pharmaceuticals, Merck Pharmaceuticals, Seattle Genetics and has received research funding from Exelixis, Seattle Genetics, and Takeda.
Jerald Radich, MD, has disclosed that he has received research funding from Novartis Pharmaceuticals and has served as a consultant or advisor for Novartis, Ariad Pharmaceuticals, and Incyte.
Elias Jabbour, MD, has disclosed that he has received research funding from Pfizer Pharmaceuticals, Ariad Pharmaceuticals, Bristol-Myers Squibb Pharmaceuticals, and Teva Pharmaceuticals.
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion: No off-label products discussed.
Accreditation Statement:The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement:The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Commercial Support Statements
This activity is supported by an educational grant from Pfizer Inc.
* Estimated time to complete this activity: 30 minutes
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 75%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
© 2015 The Johns Hopkins University. All rights reserved. No part of this enduring material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.
I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-502-7983, e-mail: HIPAA@jhmi.edu.
The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is here for training, education and/or observation purposes only.
For CME Questions, please contact the CME Office
(410) 955-2959 or e-mail firstname.lastname@example.org
For CME Certificates, please call (410) 502-9634
Johns Hopkins University School of Medicine Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)